Related references
Note: Only part of the references are listed.Recent Advances in Cancer Immunotherapy Delivery Modalities
Palaniyandi Muthukutty et al.
PHARMACEUTICS (2023)
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Dong Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Qinghua Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)
SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer
Lirui Dai et al.
FRONTIERS IN ONCOLOGY (2022)
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
Giuseppe Viscardi et al.
EUROPEAN JOURNAL OF CANCER (2022)
In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review
Muhammad Joan Ailia et al.
VACCINES (2022)
Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection
Jian-Hong Peng et al.
GASTROENTEROLOGY REPORT (2021)
Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors
Gregg L. Semenza
PHYSIOLOGY (2021)
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Vishakha Singh et al.
FRONTIERS IN PHARMACOLOGY (2021)
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo et al.
FRONTIERS IN ONCOLOGY (2021)
Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
Gaopeng Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
Jessica Carlsson et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2020)
Targeting hypoxia in tumor: a new promising therapeutic strategy
Maria Carla Bosco et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
George V. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
Yanjie Zhao et al.
MEDICINE (2020)
Turning Cold into Hot: Firing up the Tumor Microenvironment
Qianqian Duan et al.
TRENDS IN CANCER (2020)
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients
Liuxi Chen et al.
JOURNAL OF CANCER (2020)
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
Xue Han et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
Zhongyuan Fan et al.
ONCOTARGETS AND THERAPY (2019)
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer
Xiaobin Gu et al.
CANCER CELL INTERNATIONAL (2019)
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
Haotian Liao et al.
FRONTIERS IN ONCOLOGY (2019)
PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma
Xiaoli Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Pharmacologic Targeting of Hypoxia-Inducible Factors
Gregg L. Semenza
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
Boyang Chang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients
Boyang Chang et al.
LIVER INTERNATIONAL (2018)
Association of PD-L1 and HIF-1 alpha Coexpression with Poor Prognosis in Hepatocellular Carcinoma
Xiaomeng Dai et al.
TRANSLATIONAL ONCOLOGY (2018)
Immunotherapy of Hepatocellular Carcinoma
Bernd Heinrich et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Yaxiong Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Antje Tunger et al.
BIOMEDICINES (2018)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
So Young Yoo et al.
MEDIATORS OF INFLAMMATION (2017)
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
Jianhua Liu et al.
ONCOLOGY REPORTS (2017)
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
Na Li et al.
ONCOTARGET (2017)
PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
Yajuan Zhou et al.
SCIENTIFIC REPORTS (2017)
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung et al.
CANCER RESEARCH AND TREATMENT (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma
Hyeyoon Chang et al.
APMIS (2017)
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
Yih-Leong Chang et al.
EUROPEAN JOURNAL OF CANCER (2016)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
Fabian Finkelmeier et al.
EUROPEAN JOURNAL OF CANCER (2016)
Hypoxia-inducible factors: a central link between inflammation and cancer
Daniel Triner et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
Jingwei Liu et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Andrew Gabrielson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
The yin and yang of evasion and immune activation in HCC
Oxana V. Makarova-Rusher et al.
JOURNAL OF HEPATOLOGY (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
Tao Qin et al.
ONCOTARGET (2015)
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
The immune contexture of primary and metastatic human tumours
Nicolas A. Giraldo et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Targeted Therapies for Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2011)
Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
Zhen Zeng et al.
PLOS ONE (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Share Paper
